|
RDAVR
n = 48
|
TAVR
n = 104
|
p value
|
RDAVR
n = 48
|
TAVR
n = 48
|
p value
|
Age - years |
79.54±5.95 |
84.21±6.02 |
<0.001 |
79.54±5.95 |
82.60±5.75 |
0.01 |
Male gender - no./total no.(%) |
27/48 (56.25%) |
47/104 (45.19%) |
0.20 |
27/48 (56.25%) |
24/48 (50%) |
0.54 |
Body surface - m² |
1.76±0.22 |
1.73±0.19 |
0.54 |
1.76±0.22 |
1.77±0.18 |
0.71 |
Body-Mass Index - kg/m² |
24.92±3.76 |
25.64±4.74 |
0.35 |
24.92±3.76 |
26.06±4.69 |
0.19 |
EuroSCORE II - % |
6.61±1.82 |
5.76±1.48 |
0.002 |
6.61±1.82 |
5.63±1.54 |
0.005 |
Diabetes - no./total no.(%) |
9/48 (18.75%) |
35/104 (33.6%) |
0.02 |
9/48 (18.75%) |
15/48 (31.25%) |
0.16 |
Hypertension - no./total no.(%) |
41/48 (85.42%) |
78/104 (75%) |
0.14 |
41/48 (85.42%) |
38/48 (79.17%) |
0.42 |
Dyslipidemia - no./total no.(%) |
24/48 (50%) |
56/104 (53.85%) |
0.65 |
24/48 (50%) |
27/48 (56.25%) |
0.54 |
Severe renal insufficiency - no./total no.(%) |
1/48 (2.08%) |
34/104
(32.69%) |
<0.001 |
1/48 (2.08%) |
1/48 (2.08%) |
1.0 |
Creatinine clearance - mL/min |
52.51±15.92 |
36.69±15.33 |
<0.001 |
52.51±15.92 |
43.48±14.76 |
0.005 |
COPD - no./total no.(%) |
8/48 (16.67%) |
12/104 (11.54%) |
0.38 |
8/48 (16.67%) |
6/48 (12.50%) |
0.56 |
Smoke - no./total no.(%) |
15/48 (31.25%) |
31/104 (29.81%) |
0.85 |
15/48 (31.25%) |
18/48 (37.50%) |
0.52 |
Coronary artery disease - no./total no.(%) |
8/48 (16.67%) |
51/104
(49.04%) |
<0.001 |
8/48 (16.67%) |
17/48 (35.42%) |
0.04 |
Atrial fibrillation - no./total no.(%) |
15/48 (31.25%) |
53/104
(50.96%) |
0.02 |
15/48 (31.25%) |
21/48 (43.75%) |
0.21 |
Previous stroke - no./total no.(%) |
2/48 (4.17%) |
14/104 (13.46%) |
0.08 |
2/48 (4.17%) |
4/48 (8.33%) |
0.68 |
Previous cardiac surgery - no./total no.(%) |
6/48 (12.5%) |
6/104
(5.77%) |
0.19 |
6/48 (12.5%) |
5/48 (10.42%) |
0.74 |
Permanent pacemaker - no./total no.(%) |
4/48 (8.33%) |
18/104
(17.31%) |
0.14 |
4/48 (8.33%) |
8/48 (16.67%) |
0.22 |
NYHA |
|
|
0.002 |
|
|
0.39 |
I |
3/48 (6.25%) |
4/104 (3.85%) |
|
3/48 (6.25%) |
2/48 (4.17%) |
|
II |
18/48 (37.50%) |
18/104 (17.31%) |
|
18/48 (37.50%) |
11/48
(22.92%) |
|
III |
26/48 (54.17%) |
62/104 (59.62%) |
|
26/48 (54.17%) |
33/48
(68.75%) |
|
IV |
1/48 (2.08%) |
20/104 (19.23%) |
|
1/48 (2.08%) |
2/48 (4.17%) |
|
Syncope - no./total no.(%) |
1/48 (2.08%) |
3/104 (2.88%) |
0.99 |
1/48 (2.08%) |
1/48 (2.08%) |
1.0 |
Vitamin K antagonists - no./total no.(%) |
11/48 (22.92%) |
38/104
(36.54%) |
0.13 |
11/48 (22.92%) |
15/48 (31.25%) |
0.36 |
Direct oral anticoagulants - no./total no.(%) |
3/48 (6.25%) |
11/104
(10.58%) |
0.55 |
3/48 (6.25%) |
7/48 (14.58%) |
0.18 |
Mono-antiplatelet therapy - no./total no.(%) |
29/48 (60.42%) |
43/104
(41.34%) |
0.05 |
29/48 (60.42%) |
16/48 (33.33%) |
0.007 |
Dual-antiplatelet therapy - no./total no.(%) |
7/48 (14.58%) |
24/104
(23.08%) |
0.28 |
7/48 (14.58%) |
10/48 (20.83%) |
0.42 |